Intracranial Hemorrhage Rate and Lesion Burden in Patients With Familial Cerebral Cavernous Malformation

Shantel Weinsheimer, Jeffrey Nelson, Adib A Abla, Nerissa U Ko, Cynthia Tsang, Obiora Okoye, Joseph M Zabramski, Amy Akers, Atif Zafar, Marc C Mabray, Blaine L Hart, Leslie Morrison, Charles E McCulloch, Helen Kim, Brain Vascular Malformation Consortium Cerebral Cavernous Malformation Investigator Group *, Adib A Abla, Amy Akers, Issam A Awad, Blaine L Hart, Helen Kim, Nerissa U Ko, Michael T Lawton, Cornelia Lee, Marc C Mabray, Charles E McCulloch, Leslie Morrison, Ludmila Pawlikowska, Edward R Smith, Michel Torbey, Sudhakar Vadivelu, Shantel Weinsheimer, Joseph M Zabramski, Atif Zafar, Shantel Weinsheimer, Jeffrey Nelson, Adib A Abla, Nerissa U Ko, Cynthia Tsang, Obiora Okoye, Joseph M Zabramski, Amy Akers, Atif Zafar, Marc C Mabray, Blaine L Hart, Leslie Morrison, Charles E McCulloch, Helen Kim, Brain Vascular Malformation Consortium Cerebral Cavernous Malformation Investigator Group *, Adib A Abla, Amy Akers, Issam A Awad, Blaine L Hart, Helen Kim, Nerissa U Ko, Michael T Lawton, Cornelia Lee, Marc C Mabray, Charles E McCulloch, Leslie Morrison, Ludmila Pawlikowska, Edward R Smith, Michel Torbey, Sudhakar Vadivelu, Shantel Weinsheimer, Joseph M Zabramski, Atif Zafar

Abstract

Background Familial cerebral cavernous alformation (CCM) is an autosomal dominant disease caused by mutations in KRIT1, CCM2, or PDCD10. Cases typically present with multiple lesions, strong family history, and neurological symptoms, including seizures, headaches, or other deficits. Intracranial hemorrhage (ICH) is a severe manifestation of CCM, which can lead to death or long-term neurological deficits. Few studies have reported ICH rates and risk factors in familial CCM. We report ICH rates and assess whether CCM lesion burden, a disease severity marker, is associated with risk of symptomatic ICH during follow-up in a well-characterized cohort of familial CCM cases. Methods and Results We studied 386 patients with familial CCM with follow-up data enrolled in the Brain Vascular Malformation Consortium CCM Project. We estimated symptomatic ICH rates overall and stratified by history of ICH before enrollment. CCM lesion burden (total lesion count and large lesion size) assessed at baseline enrollment was tested for association with increased risk of subsequent ICH during follow-up using Cox regression models adjusted for history of ICH before enrollment, age, sex, and family structure and stratified on recruitment site. The symptomatic ICH rate for familial CCM cases was 2.8 per 100 patient-years (95% CI, 1.9-4.1). Those with ICH before enrollment had a follow-up ICH rate of 4.5 per 100 patient-years (95% CI, 2.6-8.1) compared with 2.0 per 100 patient-years (95% CI, 1.3-3.5) in those without (P=0.042). Total lesion count was associated with increased risk of ICH during follow-up (hazard ratio [HR], 1.37 per doubling of total lesion count [95% CI, 1.10-1.71], P=0.006). The symptomatic ICH rate for familial CCM cases was 2.8 per 100 patient-years (95% CI, 1.9-4.1). Those with ICH before enrollment had a follow-up ICH rate of 4.5 per 100 patient-years (95% CI, 2.6-8.1) compared with 2.0 per 100 patient-years (95% CI, 1.3-3.5) in those without (P=0.042). Total lesion count was associated with increased risk of ICH during follow-up (hazard ratio [HR], 1.37 per doubling of total lesion count [95% CI, 1.10-1.71], P=0.006). Conclusions Patients with familial CCM with prior history of an ICH event are at higher risk for rehemorrhage during follow-up. In addition, total CCM lesion burden is significantly associated with increased risk of subsequent symptomatic ICH; hence lesion burden may be an important predictor of patient outcome and aid patient risk stratification.

Keywords: cerebral cavernous malformation; familial; hemorrhage; risk factor.

Figures

Figure 1. Kaplan–Meier survival curves of hemorrhage…
Figure 1. Kaplan–Meier survival curves of hemorrhage during follow‐up in a cohort of patients with familial cerebral cavernous malformation enrolled between 2010 and 2019.
Number in parentheses is number of events that occur within each interval. Numbers at 2, 4, and 6 years indicate individuals still at risk for intracranial hemorrhage (ie, not lost to follow‐up). Figure is truncated at 6 years (includes most data). Hem indicates hemorrhage.

References

    1. Labauge P, Brunereau L, Laberge S, Houtteville JP. Prospective follow‐up of 33 asymptomatic patients with familial cerebral cavernous malformations. Neurology. 2001;57:1825–1828. doi: 10.1212/WNL.57.10.1825
    1. Zabramski JM, Wascher TM, Spetzler RF, Johnson B, Golfinos J, Drayer BP, Brown B, Rigamonti D, Brown G. The natural history of familial cavernous malformations: results of an ongoing study. J Neurosurg. 1994;80:422–432. doi: 10.3171/jns.1994.80.3.0422
    1. Al‐Shahi Salman R, Hall JM, Horne MA, Moultrie F, Josephson CB, Bhattacharya JJ, Counsell CE, Murray GD, Papanastassiou V, Ritchie V, et al. Untreated clinical course of cerebral cavernous malformations: a prospective, population‐based cohort study. Lancet Neurol. 2012;11:217–224. doi: 10.1016/S1474-4422(12)70004-2
    1. Morris Z, Whiteley WN, Longstreth WT Jr, Weber F, Lee YC, Tsushima Y, Alphs H, Ladd SC, Warlow C, Wardlaw JM, et al. Incidental findings on brain magnetic resonance imaging: systematic review and meta‐analysis. BMJ. 2009;339:b3016. doi: 10.1136/bmj.b3016
    1. Moore SA, Brown RD Jr, Christianson TJ, Flemming KD. Long‐term natural history of incidentally discovered cavernous malformations in a single‐center cohort. J Neurosurg. 2014;120:1188–1192. doi: 10.3171/2014.1.JNS131619
    1. Snellings DA, Hong CC, Ren AA, Lopez‐Ramirez MA, Girard R, Srinath A, Marchuk DA, Ginsberg MH, Awad IA, Kahn ML. Cerebral cavernous malformation: from mechanism to therapy. Circ Res. 2021;129:195–215. doi: 10.1161/CIRCRESAHA.121.318174
    1. Choquet H, Nelson J, Pawlikowska L, McCulloch CE, Akers A, Baca B, Khan Y, Hart B, Morrison L, Kim H. Association of cardiovascular risk factors with disease severity in cerebral cavernous malformations type 1 subjects with the common Hispanic mutation. Cerebrovasc Dis. 2014;37:57–63. doi: 10.1159/000356839
    1. Choquet H, Trapani E, Goitre L, Trabalzini L, Akers A, Fontanella M, Hart BL, Morrison LA, Pawlikowska L, Kim H, et al. Cytochrome P450 and matrix metalloproteinase genetic modifiers of disease severity in cerebral cavernous malformation type 1. Free Radic Biol Med. 2016;92:100–109. doi: 10.1016/j.freeradbiomed.2016.01.008
    1. Tang AT, Choi JP, Kotzin JJ, Yang Y, Hong CC, Hobson N, Girard R, Zeineddine HA, Lightle R, Moore T, et al. Endothelial TLR4 and the gut microbiome drive cerebral cavernous malformations. Nature. 2017;545:305–310. doi: 10.1038/nature22075
    1. Akers A, Al‐Shahi Salman R, Awad IA, Dahlem K, Flemming K, Hart B, Kim H, Jusue‐Torres I, Kondziolka D, Lee C, et al. Synopsis of guidelines for the clinical management of cerebral cavernous malformations: consensus recommendations based on systematic literature review by the Angioma Alliance Scientific Advisory Board Clinical Experts Panel. Neurosurgery. 2017;80:665–680. doi: 10.1093/neuros/nyx091
    1. Labauge P, Brunereau L, Levy C, Laberge S, Houtteville JP. The natural history of familial cerebral cavernomas: a retrospective MRI study of 40 patients. Neuroradiology. 2000;42:327–332. doi: 10.1007/s002340050893
    1. Santos AN, Rauschenbach L, Saban D, Chen B, Oppong MD, Herten A, Gull HH, Rieb C, Deuschl C, Schmidt B, et al. Multiple cerebral cavernous malformations: clinical course of confirmed, assumed and non‐familial disease. Eur J Neurol. 2022;29:1427–1434. doi: 10.1111/ene.15253
    1. Gross BA, Du R. Hemorrhage from cerebral cavernous malformations: a systematic pooled analysis. J Neurosurg. 2017;126:1079–1087. doi: 10.3171/2016.3.JNS152419
    1. Petersen TA, Morrison LA, Schrader RM, Hart BL. Familial versus sporadic cavernous malformations: differences in developmental venous anomaly association and lesion phenotype. AJNR Am J Neuroradiol. 2010;31:377–382. doi: 10.3174/ajnr.A1822
    1. Choquet H, Pawlikowska L, Nelson J, McCulloch CE, Akers A, Baca B, Khan Y, Hart B, Morrison L, Kim H. Polymorphisms in inflammatory and immune response genes associated with cerebral cavernous malformation type 1 severity. Cerebrovasc Dis. 2014;38:433–440. doi: 10.1159/000369200
    1. Zou X, Hart BL, Mabray M, Bartlett MR, Bian W, Nelson J, Morrison LA, McCulloch CE, Hess CP, Lupo JM, et al. Automated algorithm for counting microbleeds in patients with familial cerebral cavernous malformations. Neuroradiology. 2017;59:685–690. doi: 10.1007/s00234-017-1845-8
    1. Al‐Shahi Salman R, Berg MJ, Morrison L, Awad IA, Angioma Alliance Scientific Advisory Board . Hemorrhage from cavernous malformations of the brain: definition and reporting standards. Angioma Alliance scientific advisory board. Stroke. 2008;39:3222–3230. doi: 10.1161/STROKEAHA.108.515544
    1. Carrion‐Penagos J, Zeineddine HA, Polster SP, Girard R, Lyne SB, Koskimäki J, Romanos S, Srinath A, Zhang D, Cao Y, et al. Subclinical imaging changes in cerebral cavernous angiomas during prospective surveillance. J Neurosurg. 2020;134:1147–1154. doi: 10.3171/2020.1.JNS193479
    1. Santos AN, Rauschenbach L, Saban D, Chen B, Herten A, Dinger TF, Li Y, Tippelt S, Marina AD, Dohna‐Schwake C, et al. Natural course of cerebral cavernous malformations in children: a five‐year follow‐up study. Stroke. 2022;53:817–824. doi: 10.1161/STROKEAHA.121.035338
    1. Lanfranconi S, Piergallini L, Ronchi D, Valcamonica G, Conte G, Marazzi E, Manenti G, Bertani GA, Locatelli M, Triulzi F, et al. Clinical, neuroradiological and genetic findings in a cohort of patients with multiple cerebral cavernous malformations. Metab Brain Dis. 2021;36:1871–1878. doi: 10.1007/s11011-021-00809-1

Source: PubMed

3
订阅